Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 153

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 153
---

receives debt financing, it will have priority in any liquidation over the claims of holders of its stockholders, which could increase
the risk of loss of your investment. In addition, DiamiR’s payment obligations with respect to any indebtedness could divert funds
away from its operations, marketing and product development efforts.

The ongoing uncertainty in global economic conditions may negatively impact DiamiR’s business, operating results or financial condition.

The continuing unfavorable global economic conditions and uncertainty
have caused a general tightening in the credit markets, lower levels of liquidity, increases in the rates of default and bankruptcy and
extreme volatility in credit, equity and fixed income markets. These macroeconomic conditions could negatively affect DiamiR’s business,
operating results or financial condition in a number of ways. For example, potential future clients may be unable to fund purchases of
products and services, which could cause them to delay, decrease or cancel purchases of DiamiR’s products and services or to not
pay DiamiR or to delay paying DiamiR for previously purchased products and services. DiamiR’s clients may cease business operations
or conduct business on a greatly reduced basis.

DiamiR faces significant, evolving competition which, if it fails to properly address, could adversely affect its business, results of operations, and financial condition.

The markets for molecular diagnostics are intensely competitive, and
DiamiR faces significant competition from a number of different sources. Several of DiamiR’s competitors have substantially greater
name recognition and financial, technical, product development and marketing resources than DiamiR does. There has been significant merger
and acquisition activity among a number of its competitors in recent years. Transaction induced pressures, or other related factors
may result in negative market dynamics that could adversely affect DiamiR’s business, results of operations and financial condition.

DiamiR competes in all of its markets with other major molecular diagnostics
companies. Competitive pressures and other factors, such as new product introductions by DiamiR or its competitors, may result in price
or market share erosion that could adversely affect its business, results of operations and financial condition. Also, there can be no
assurance that DiamiR’s products will achieve broad market acceptance or will successfully compete with other similar products available
in the market.

DiamiR may engage in future acquisitions, which may be expensive and time consuming and from which it may not realize anticipated benefits.

DiamiR may acquire additional businesses, technologies, and products
if DiamiR determines that